ST Shuangcheng: Expected net loss of 13-19 million yuan in the first half of the year.

ST Shuangcheng released the performance forecast for the first half of 2025, expecting a net loss of 13 to 19 million yuan attributable to the shareholders of the listed company, compared to a loss of 16.9462 million yuan in the same period last year. During the reporting period, the pharmaceutical industry underwent continuous reforms, with significant changes in market supply and demand and prices. The sales volume of products that did not win bids in centralized procurement decreased significantly, while the prices of winning bid products dropped sharply. The company's main product, Thymosin Alpha-1 for injection, saw a decrease in domestic sales profit due to a price reduction in the new bidding period for centralized procurement. In May 2025, the application for a simplified new drug for Paclitaxel for injection was approved by the Food and Drug Administration in the United States and has been granted permission for export sales. Additionally, the export revenue for Betalutin for injection products increased, leading to an improvement in export profits. These factors resulted in overall performance changes not being significant.